AvalehtGNLX • NASDAQ
add
Genelux Corp
Viimane sulgemishind
2,42 $
Tänane vahemik
2,43 $ - 2,72 $
Aasta vahemik
1,60 $ - 5,89 $
Turuväärtus
99,45 mln USD
Keskmine maht
192,42 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Uudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Käive | 0,00 | — |
Põhitegevusega seonduv kulu | 9,75 mln | 39,24% |
Puhastulu | −8,98 mln | −32,64% |
Puhaskasumimarginaal | — | — |
Puhaskasum aktsia kohta | −0,26 | −4,00% |
EBITDA | −9,69 mln | −40,33% |
Tõhus maksumäär | — | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 30,90 mln | 33,22% |
Kogu vara | 34,72 mln | 24,46% |
Kõik kohustused | 8,44 mln | 0,26% |
Kogu omakapital | 26,27 mln | — |
Emiteeritud aktsiate arv | 34,17 mln | — |
Hinna ja väärtuse suhe P/B | 3,15 | — |
Varade tasuvus | −65,00% | — |
Kapitali tasuvus | −77,03% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | dets 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | −8,98 mln | −32,64% |
Põhitegevuse rahakäive | −4,30 mln | 37,74% |
Investeeringute raha | 6,67 mln | 147,87% |
Finantseerimise raha | 91,00 tuh | −77,31% |
Raha ja raha ekvivalentide muutus | 2,46 mln | 112,04% |
Tasuta rahavoog | −1,37 mln | 70,63% |
Teave
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Asutatud
2001
Veebisait
Töötajate arv
24
